Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

NCT05163249 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Osimertinib
DRUG: Savolitinib

Sponsor

Guangdong Association of Clinical Trials